Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PreventiOn of DYSbioSis Complications With Autologous Fecal Microbiota Transplantation in acutE myEloid Leukemia Patients Undergoing Intensive Treatment: A Feasibility and Safety Study ODYSSEE STUDY

Next Previous
Trial Profile

PreventiOn of DYSbioSis Complications With Autologous Fecal Microbiota Transplantation in acutE myEloid Leukemia Patients Undergoing Intensive Treatment: A Feasibility and Safety Study ODYSSEE STUDY

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 03 Oct 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Maa-T-013 (Primary)
  • Indications Acute myeloid leukaemia; Dysbiosis
  • Focus Proof of concept; Therapeutic Use
  • Acronyms ODYSSEE
  • Sponsors MaaT Pharma

    • Most Recent Events

    • 25 May 2021 Results published in the MaaT Pharma Media Release.
    • 25 May 2021 Primary endpoint has been met. (Evaluation of AFMT efficacy in MDRB eradication based on bacterial culture), according to a MaaT Pharma media release.
    • 25 May 2021 Primary endpoint has been met. (Evaluation of AFMT efficacy in dysbiosis correction by measure of microbiota diversity), according to a MaaT Pharma media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top